肿瘤药学Issue(6)：459-462,4.DOI:10.3969/j.issn.2095-1264.2013.112
吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血液学不良反应观察
Observation on the Short-Term Clinical Effects and Hematologic Adverse Reactions of Gemcitabine Combined with Oxaliplatin in the Treatment of Advanced Malignant Tumor
陈芳 1姜雪秋 1许一清 1冯国安 1邢丰1
作者信息
- 1. 大丰市人民医院，江苏 大丰，224200
- 折叠
摘要
Abstract
Objective To discuss the short-term effects and hematologic adverse reactions in the treatment of advanced ma-lignant tumors with gemcitabine plus oxaliplatin. Methods Seventy-six patients with advanced malignant tumor treated in our hospital between Jan. 2010 and Dec. 2012 were randomly selected and divided into the single-agent gemcitabine treatment group (Monotherapy group ) and the gemcitabine and oxaliplatin treatment group (Combination group). After two cycles of chemo-therapy, the efficacy and hematologic adverse reactions in the two groups were compared and analyzed. Results The total remis-sion rate in the Combination group was 71.05%, higher than that of the monotherapy group (52.63%, P<0.05). However, the hematologic adverse reactions such as neutropenia, thrombocytopenia and asphaerinia in the Combination group were also higher than that in the monotherapy group (P<0.05). Conclusion The combination of gemcitabine and oxaliplatin in the treatment for advanced malignant tumor can improve the shor term effects but could cause greater hematologic adverse reactions. It is necessary to pay more attention to apply the combination therapy in clinic.关键词
吉西他滨/奥沙利铂/联合治疗/晚期恶性肿瘤/不良反应Key words
Oxaliplatin/Gemcitabine/Combined therapy/Malignant tumor/Adverse reaction分类
医药卫生引用本文复制引用
陈芳,姜雪秋,许一清,冯国安,邢丰..吉西他滨联合奥沙利铂治疗晚期恶性肿瘤的近期疗效和血液学不良反应观察[J].肿瘤药学,2013,(6):459-462,4.
